COVID-19 - July 15, 2021
New findings about Vaxzevria’s induced immunity
A sub-analysis from the Oxford-led COV001 and COV002 trials with Vaxzevria induced strong immune responses following either a prolonged second dose interval of up to 45 weeks or following a third boosting dose. The results, published by the University of Oxford on the pre-print server of The Lancet, demonstrated that antibody levels remain elevated from baseline for […]
COVID-19 - July 14, 2021
Vaccibody enters license agreement with Adaptive Biotechnologies
Vaccibody has entered into an exclusive agreement with Adaptive Biotechnologies to use a broad selection of virus-specific T cell epitopes identified by Adaptive for Vaccibody to design and develop novel SARS-CoV-2 vaccines. Under the terms of the license agreement, Adaptive has provided certain selected T-cell epitopesfor exclusive use in Vaccibody’s next-generation SARS-CoV-2 vaccines. Vaccibody will […]
COVID-19 - July 14, 2021
Cyxone completes Rabeximod COVID-19 Phase 2 trial
The Phase 2 Covid-19 trial of Rabeximod that has been conducted in Eastern Europe during Q1-Q2 2021 will be closed as the trial has been shown to have a sufficient number of patients enrolled to allow for statistical analysis. Recently Cyxone reported that patient recruitment for the clinical study conducted in Covid-19 patients in Eastern […]
COVID-19 - July 14, 2021
Encouraging results from BerGenBio
BerGenBio has presented a combined analysis of data from two Phase II studies investigating bemcentinib in hospitalised COVID-19 patients. Data was presented from the UKRI PhaseII ACCORD2 platform study, sponsored by University Hospital Southampton, UK and BGBC020, BerGenBio’s open-label Phase II study conducted in South Africa and India. In total, 179 eligible patients were enrolled […]
COVID-19 - July 12, 2021
Researchers have identified genetic risk factors for severe COVID-19
A comprehensive summary, based on the analyses of nearly 50,000 patients and published in Nature, reveals 13 genetic regions that are strongly associated with infection or severe COVID-19. Why do some people get severely ill from COVID-19? In addition to risk factors such as age and diabetes, some of this is attributable to our varying […]
COVID-19 - June 30, 2021
Vaccibody to initiate a phase 1/2 vaccine trial
Vaccibody is initiating a phase 1/2, open label, dose escalation trial in healthy adult volunteers to determine safety and immunogenicity of two SARS CoV-2 virus DNA vaccine candidates. Vaccibody’s development strategy is to develop second-generation SARS CoV-2 vaccines that may respond to the emerging threats of evolving variants with reduced sensitivity to first generation vaccines […]
